03:46 AM EST, 11/28/2025 (MT Newswires) -- Protagenic Therapeutics ( PTIX ) said Thursday it received a Nasdaq notice for failing to meet the minimum $2.5 million stockholders' equity requirement and for not filing its quarterly report on time.

The company said Nasdaq flagged its recently reported equity levels and the delayed Form 10-Q for the quarter ended Sept. 30, 2025. Because the company had only recently regained compliance and remains under a mandatory panel monitoring period, Nasdaq has moved to delist its shares.

The company said it will request a hearing, which automatically halts any suspension for 15 days, and will also seek an additional stay while the panel reviews its case.